Active group ablation: In patients in the active group, changes in fibrillation dynamics induced by CPVI and ablation of DFASI domains will be evaluated, as suggested by our preliminary results (Calvo D et al. Sci Rep. 2025 Dec 16;15(1):43892). Therefore, an experimental protocol will be carried out in which, after CPVI, each DFASI domain will be addressed sequentially. The following will be determined: a) changes in hierarchical organization levels, b) the formation of new DFASI domains; c) if AF ends after ablation, the termination mechanisms will be described. Once all ablation sets on the identified DFASI reentrant domains have been completed, noninvasive maps will be acquired under the effect of adenosine in order to compare fibrillatory dynamics under basal adenosine vs. post-ablation.
Control group ablation: Therefore, an experimental protocol will be carried out in which, once the CPVI has been completed, a new acquisition of non-invasive maps will be performed to characterize the basal fibrillation dynamics and those under adenosine.
Study summary
The mechanisms that maintain persistent atrial fibrillation (AF) in humans remain unknown. In the research project PI18/01268 funded in the previous call for Strategic Action in Health, the group has demonstrated that the hierarchical organization of (i) rotational domains, (ii) frequency domains and (iii) physiological responses to pharmacological provocation with adenosine, allow the identification of domains of high-frequency reentrant activity (hereinafter "DFASI domains") maintainers of AF. As a result, the investigators have developed non-invasive technological models and quantitative indices for the efficient localization of these domains, whose therapeutic approach through ablation has allowed to improve the clinical results of the patients studied, safely without increase in complications (Calvo D et al. Sci Rep. 2025 Dec 16;15(1):43892). Likewise, and in response to the objectives of the PI18/01268 project, the investigators have identified hierarchical organization patterns in human ventricular fibrillation (VF) that indicate the existence of universal fibrillatory mechanisms, opening the door to new therapeutic opportunities (Europace 2022;24\[11\]:1788-1799).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients over 18 years of age with persistent AF lasting more than 6 months at the time of the experimental protocol (uninterrupted persistent AF) and clinical indication for an AF ablation procedure.
or
-Patients over 18 years of age with recurrent VF/VT and poor control with conventional pharmacological measures.
Exclusion Criteria:
* Lack of patient consent to participate in the study.
* In patients with persistent AF, contraindication for the use of adenosine.
* AF/VF/VPT secondary to endocrine-metabolic disorders and/or severe systemic disease (thyrotoxicosis, sepsis, pulmonary thromboembolism, etc.).
* Contraindications for cardiac catheterization (e.g., intracardiac thrombus).
* Impossibility of remote monitoring using an implantable Holter monitor or implantable defibrillator.
Primary outcome measure(s)
Mapping for the identification of stable reentrant domains with high activation frequency in persistent AF. — During procedure After performing cardiac CT, non-invasive mapping will be performed using ECGi non-invasive map system. The signals will be analyzed for real-time inverse solution calculations using proprietary spectral fingerprint identification algorithms (Calvo D et al. Sci Rep. 2025 Dec 16;15(1):43892). In particular, non-invasive mapping will provide the fibrillation signal from both atria for the implementation of the calculations necessary for the spectral fingerprint study. The instantaneous phase will be computed by two methods: (i) by Hilbert transformation of the signal; and (ii) by phase calculation on the discrete frequencies identified in the power spectrogram. On the other hand, invasive mapping will be used to process bipolar and unipolar cardiac signals in order to analyze hierarchically organized patterns.
Effects of ablation of DFSAI > 0.8 domains on fibrillation dynamics and sustainability — During procedure * In patients in the active group, changes in fibrillation dynamics induced by CPVI and ablation of DFASI domains will be evaluated, as suggested by our preliminary results (Calvo D et al. Sci Rep. 2025 Dec 16;15(1):43892). Therefore, an experimental protocol will be carried out in which, after CPVI, each DFASI domain will be addressed sequentially. The following will be determined: a) changes in hierarchical organization levels, b) the formation of new DFASI domains; c) if AF ends after ablation, the termination mechanisms will be described. Once all ablation sets on the identified DFASI reentrant domains have been completed, noninvasive maps will be acquired under the effect of adenosine in order to compare fibrillatory dynamics under basal adenosine vs. post-ablation.
* In patients in the control group, once CPVI is completed new noninvasive maps will be acquired to characterize basal and adenosine-induced fibrillatory dynamics.
Effects of ablation of reentrat domains of human ventricular fibrillation on arrhythmia inducibility. — Procedure Adapt the model to patients with ventricular arrhythmias such as polymorphic ventricular tachycardia and/or VF. After performing a cardiac CT scan, non-invasive mapping will be performed using ECGi non-invasive map system. The signals will be analyzed for real-time inverse solution calculations using algorithms for identifying reentrant domains and their correlation with hierarchical organization patterns (Calvo D et al. Sci Rep. 2025 Dec 16;15(1):43892). To this end, VF will be induced by programmed stimulation on two occasions in order to identify the hierarchical organization of the stability of rotational activity in terms of frequency. Ablation will follow and inducibility tested as measurement of efficacy.
Arrhythmia burden during Follow-up — 3, 6 and 12 months follow-up visits A subcutaneous Holter monitor will be implanted one month prior to the ablation procedure to mesure arrhythmia burden (Atrial fibrillation; number of recurrences and hours per day). Patients will be monitored continuously after the ablation procedure using remote subcutaneous Holter monitoring platforms and in person at cardiology consultations at 3, 6, and 12 months, at a minimum.
Patients with VF ablation will be followed up after the ablation procedure on an ongoing basis using implantable defibrillator remote monitoring platforms and in person at cardiology consultations at least 3, 6, and 12 months after the procedure. The arrhythmia burden will be measure as a function of number of recurrences per follow-up time.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.